Pacer Advisors Inc. Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Pacer Advisors Inc. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 19.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 561,834 shares of the biotechnology company’s stock after acquiring an additional 92,240 shares during the period. Pacer Advisors Inc. owned 1.26% of United Therapeutics worth $178,972,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. SG Americas Securities LLC increased its stake in shares of United Therapeutics by 176.2% during the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after buying an additional 4,100 shares during the last quarter. Comerica Bank boosted its holdings in United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares in the last quarter. QRG Capital Management Inc. boosted its holdings in United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after acquiring an additional 1,692 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC grew its stake in shares of United Therapeutics by 163.8% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,245 shares of the biotechnology company’s stock worth $1,813,000 after acquiring an additional 5,120 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

UTHR stock opened at $353.00 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The company has a market cap of $15.70 billion, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. The stock’s fifty day moving average price is $338.55 and its 200-day moving average price is $290.39.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter last year, the company earned $5.24 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,076.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,076.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The disclosure for this sale can be found here. Insiders have sold 110,922 shares of company stock worth $36,541,398 in the last 90 days. 12.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on UTHR. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. Bank of America cut their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a research report on Thursday, August 1st. Finally, Wells Fargo & Company upped their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.